Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Rare Disease
Lilly buys into Precision gene-editing platform
by Lisa M. Jarvis
November 27, 2020
| A version of this story appeared in
Volume 98, Issue 46
Eli Lilly and Company will pay $100 million for access to Precision BioSciences’ gene-editing platform. The partners will work together to develop treatments for Duchenne muscular dystrophy and other genetic diseases. Although many big companies have invested in the CRISPR-Cas9 gene-editing system, Lilly’s partnership with Precision taps into an older platform that uses an algae-derived enzyme called I-CreI. It can make highly specific snips to a gene and features a built-in off switch. Lilly will also take a stake in Precision worth $35 million.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X